Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7547627 | 0.86 | ALDH1A1 (0.59) | HSP90AA1HSP90AB1POLBTDP1KMT2A | |
| SCHEMBL10242035 | 0.83 | MAOA (0.59) | POLBTP53KMT2ANPC1RAB9A | |
| SCHEMBL2853227 | 0.83 | ALDH1A1 (0.64) | POLBKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL3012871 | 0.83 | POLB (0.70) | POLBTP53KMT2AALDH1A1NPC1 | |
| SCHEMBL18155290 | 0.82 | ALOX15 (0.55) | HSP90AA1HSP90AB1POLBTP53KMT2A | |
| SCHEMBL11563350 | 0.82 | POLB (0.53) | HSP90AA1HSP90AB1POLBKMT2AALDH1A1 | |
| SCHEMBL10242069 | 0.82 | KMT2A (0.71) | HSP90AA1HSP90AB1POLBTP53KMT2A | |
| SCHEMBL15678237 | 0.81 | KMT2A (0.54) | HSP90AA1HSP90AB1KMT2AALDH1A1NPC1 | |
| SCHEMBL9115026 | 0.81 | NMT1 (0.63) | POLBTDP1KMT2AALDH1A1GAA | |
| SCHEMBL4689214 | 0.80 | ALDH1A1 (0.47) | HSP90AA1HSP90AB1POLBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359082-A1 | HER2 MUTATION INHIBITORS | Array BioPharma Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024059558-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023111996-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE HOLDING, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022003575-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210017134-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20180265471-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-20170298023-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20150105432-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. | 2015-04-16 | — | — | US | disclosed |
| EP-2624833-B1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| EP-2624833-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | Otsuka Pharmaceutical Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012046825-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007071840-A2 | COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF | CEREP (FR) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105432-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, IDH2, GLS2 | HSP90AA1 1441/4885HSP90AB1 1166/4885POLB 3045/4885 |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, MDH2, IDH2 | HSP90AA1 1323/4885HSP90AB1 1040/4885POLB 2853/4885 |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | HSP90AA1 1500/4885HSP90AB1 811/4885POLB 3223/4885 |
| US-20180265471-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | HSP90AA1 1435/4885HSP90AB1 1159/4885POLB 3031/4885 |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | HSP90AA1 3295/4885HSP90AB1 2345/4885POLB 1631/4885 |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | HSP90AA1 1458/4885HSP90AB1 781/4885POLB 2914/4885 |
| US-20170298023-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | IDH2, MDH2, HCCS | HSP90AA1 1426/4885HSP90AB1 1141/4885POLB 2657/4885 |
| US-20210017134-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | HSP90AA1 1435/4885HSP90AB1 1159/4885POLB 3031/4885 |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | HSP90AA1 1458/4885HSP90AB1 781/4885POLB 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.